Details

Autor(en) / Beteiligte

• Larkin, James
• Chiarion-Sileni, Vanna
• Gonzalez, Rene
• Grob, Jean Jacques
• Cowey, C. Lance
• Lao, Christopher D
• Schadendorf, Dirk
• Dummer, Reinhard
• Smylie, Michael
• Rutkowski, Piotr
• Ferrucci, Pier F
• Hill, Andrew
• Wagstaff, John
• Carlino, Matteo S
• Haanen, John B
• Maio, Michele
• Marquez-Rodas, Ivan
• McArthur, Grant A
• Ascierto, Paolo A
• Long, Georgina V
• Callahan, Margaret K
• Postow, Michael A
• Grossmann, Kenneth
• Sznol, Mario
• Dreno, Brigitte
• Bastholt, Lars
• Yang, Arvin
• Rollin, Linda M
• Horak, Christine
• Hodi, F. Stephen
• Wolchok, Jedd D

Titel

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

Ist Teil von

• The New England journal of medicine, 2015-07, Vol.373 (1), p.23-34

Ort / Verlag

United States: Massachusetts Medical Society

Erscheinungsjahr

2015

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• The addition of nivolumab (anti–PD-1) to ipilimumab (anti–CTLA-4) did not further improve response rate or progression-free survival among patients with PD-L1–positive tumors. The combination was much more effective in patients with PD-L1–negative tumors. Considerable progress in the treatment of metastatic melanoma has been made in the past 5 years, with the approval of immune checkpoint–blocking antibodies and, in parallel, agents targeting aberrant signaling in the 40 to 50% of melanomas with BRAF mutations. 1 – 6 Ipilimumab, an anti–cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) antibody, acts to up-regulate antitumor immunity and was the first agent to be associated with an improvement in overall survival in a phase 3 study involving patients with metastatic melanoma. 5 , 6 Ipilimumab was associated with responses in 10% and 15% of patients 5 , 6 ; approximately 20% of treated patients had long-term survival. . . .